Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mai Oushy

Family Medicine Las Cruces, NM Medical Doctor

NPI 1386027530 CMS profile 1368827

4672 N Sonoma Ranch Blvd Ste B, Las Cruces, NM 88011

Open in the dashboard

General payments

$2,937

155 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mai Oushy of Las Cruces, NM is reported in the CMS Open Payments database as having received $2,937 across 155 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $508 25
2024 General $434 19
2023 General $395 19
2022 General $336 19
2021 General $635 43
2020 General $277 15
2019 General $352 15

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mai Oushy
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to Mai Oushy were reported at $508. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year Mai Oushy Family Medicine median Middle half National median
2019 $352 $150 $41–$543 $163
2020 $277 $120 $32–$415 $114
2021 $635 $137 $35–$551 $132
2022 $336 $137 $37–$512 $149
2023 $395 $149 $42–$545 $160
2024 $434 $156 $44–$560 $164
2025 $508 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Lilly USA, LLC $703 40 payments
  2. AstraZeneca Pharmaceuticals LP $651 26 payments
  3. Novo Nordisk Inc $535 39 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $343 13 payments
  5. Abbott Laboratories $128 6 payments
  6. AbbVie, Inc. $113 6 payments
  7. GlaxoSmithKline, LLC. $92 7 payments
  8. Amarin Pharma Inc. $83 4 payments
  9. Exact Sciences Corporation $51 3 payments
  10. Xeris Pharmaceuticals, Inc. $44 2 payments
  11. Other $194 9 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,932 154 payments
  2. Education $5 1 payment
Products named General payments · program years 2019–2025
  1. FARXIGA $474 15 payments
  2. Ozempic $368 29 payments
  3. AIRSUPRA $362 8 payments
  4. RYBELSUS $311 25 payments
  5. JARDIANCE Diabetes $273 17 payments
  6. TRULICITY $238 15 payments
  7. JARDIANCE Diabetes $235 8 payments
  8. MOUNJARO $218 11 payments
  9. EMGALITY $192 11 payments
  10. REYVOW $164 9 payments
  11. Other $1,259 72 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 90 drugs

Part D claims

3,972

Median for Family Practice: 1,826

Drug cost

$666,060

Median for Family Practice: $120,094

Branded share of claims

20.9%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 154 $249,588
Mounjaro Tirzepatide Brand 64 $104,239
Trulicity Dulaglutide Brand 36 $74,295
Biktarvy Bictegrav/Emtricit/Tenofov Ala Brand 14 $53,880
Farxiga Dapagliflozin Propanediol Brand 28 $37,497
Eliquis Apixaban Brand 20 $26,315
Januvia Sitagliptin Phosphate Brand 19 $25,392
Jardiance Empagliflozin Brand 16 $25,258
Tresiba Flextouch U-100 Insulin Degludec Brand 18 $10,363
Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate Brand 20 $5,894

The 10 drugs with the highest cost, of 90 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 44 billing codes

Paid by Medicare

$103,941

Of which drugs: $908

Medicare patients

237

Average age 73

Services billed

1,630

172 women, 65 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 36%
Diabetes 30%
Osteoporosis 22%
Chronic kidney disease 21%
Ischemic heart disease 13%
Cancer 10%
Depression 8%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FARXIGA
  • AstraZeneca Pharmaceuticals LP $83
$83 28 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $67
$67 — —
MOUNJARO
  • Lilly USA, LLC $53
$53 64 —
VRAYLAR
  • AbbVie, Inc. $44
$44 — —
RYBELSUS
  • Novo Nordisk Inc $36
$36 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

155 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in New Mexico

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record